Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more ...
4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...
Patriots head coach Mike Vrabel jabs Travis Hunter, tells prospect he's 'not the only one to play two ways'
T he most unique prospect in recent memory to come through the NFL Draft is Colorado's Travis Hunter. Why? Well, he just ...
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
Targeted Oncology17h
FDA Grants Priority Review to TLX250-CDx in Kidney Cancer
The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, ...
legit18h
Lady Schooling in Canada Shares Messages She Received from Man in His 40s Whom She Rejected
An international student has displayed the messages a man in his 40s sent her on WhatsApp because she rejected him. The ...
ophthalmologytimes19h
Outlook Therapeutics resubmits BLA for ONS-5010 for treatment of wet AMD
Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...
pulmonologyadvisor20h
FDA Drug Approval Decisions Expected in March 2025
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...